FMOC-L-THR (AZP-531) is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight. The O-glycosidic linkage and the O-acetyl protection in this building block is stable to both piperidine and TFA, making it completely compatible with standard protocols in Fmoc solid phase peptide synthesis. The Tn antigen is a tumor-associated carbohydrate antigen that is not normally expressed in peripheral tissues or blood cells. Expression of this antigen, which is found in a majority of human carcinomas of all types, arises from a blockage in the normal O-glycosylation pathway in which glycans are extended from the common precursor GalNAcα1-O-Ser Thr (Tn +antigen)[1].
Gynosaponin TN-2, demonstrating anti-Parkinsonian activity, mitigates L-DOPA (100 and 200 μM)-induced apoptotic cell death in pheochromocytoma 12 cells through the modulation of extracellular signal-regulated protein kinases 1 and 2 activation.